Anebulo Pharmaceuticals, Inc.

NasdaqCM:ANEB Voorraadrapport

Marktkapitalisatie: US$37.9m

Anebulo Pharmaceuticals Beheer

Beheer criteriumcontroles 1/4

Momenteel beschikken wij niet over voldoende informatie over de CEO.

Belangrijke informatie

Richie Cunningham

Algemeen directeur

US$1.8m

Totale compensatie

Percentage CEO-salaris18.3%
Dienstverband CEO1.1yrs
Eigendom CEOn/a
Management gemiddelde ambtstermijn1.8yrs
Gemiddelde ambtstermijn bestuur3.7yrs

Recente managementupdates

Recent updates

Here's Why We're Watching Anebulo Pharmaceuticals' (NASDAQ:ANEB) Cash Burn Situation

Jun 22
Here's Why We're Watching Anebulo Pharmaceuticals' (NASDAQ:ANEB) Cash Burn Situation

Is Anebulo Pharmaceuticals (NASDAQ:ANEB) In A Good Position To Deliver On Growth Plans?

Feb 18
Is Anebulo Pharmaceuticals (NASDAQ:ANEB) In A Good Position To Deliver On Growth Plans?

Is Anebulo Pharmaceuticals (NASDAQ:ANEB) In A Good Position To Invest In Growth?

Jul 03
Is Anebulo Pharmaceuticals (NASDAQ:ANEB) In A Good Position To Invest In Growth?

Companies Like Anebulo Pharmaceuticals (NASDAQ:ANEB) Are In A Position To Invest In Growth

Mar 07
Companies Like Anebulo Pharmaceuticals (NASDAQ:ANEB) Are In A Position To Invest In Growth

We Think Anebulo Pharmaceuticals (NASDAQ:ANEB) Can Afford To Drive Business Growth

Nov 19
We Think Anebulo Pharmaceuticals (NASDAQ:ANEB) Can Afford To Drive Business Growth

Anebulo Pharmaceuticals to launch private investment in public equity financing

Sep 26

Anebulo Pharmaceuticals GAAP EPS of -$0.10 misses by $0.03

Sep 09

Here's Why We're Not Too Worried About Anebulo Pharmaceuticals' (NASDAQ:ANEB) Cash Burn Situation

Jun 28
Here's Why We're Not Too Worried About Anebulo Pharmaceuticals' (NASDAQ:ANEB) Cash Burn Situation

Companies Like Anebulo Pharmaceuticals (NASDAQ:ANEB) Are In A Position To Invest In Growth

Mar 15
Companies Like Anebulo Pharmaceuticals (NASDAQ:ANEB) Are In A Position To Invest In Growth

Here's Why We're Not Too Worried About Anebulo Pharmaceuticals' (NASDAQ:ANEB) Cash Burn Situation

Nov 04
Here's Why We're Not Too Worried About Anebulo Pharmaceuticals' (NASDAQ:ANEB) Cash Burn Situation

Anebulo Pharmaceuticals reports FQ3 results

Jun 21

Analyse CEO-vergoeding

Hoe is Richie Cunningham's beloning veranderd ten opzichte van Anebulo Pharmaceuticals's winst?
DatumTotale vergoedingSalarisBedrijfswinsten
Sep 30 2024n/an/a

-US$8m

Jun 30 2024US$2mUS$333k

-US$8m

Compensatie versus markt: De totale vergoeding ($USD 1.82M ) Richie } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 649.63K ).

Compensatie versus inkomsten: Er zijn onvoldoende gegevens om de beloning van Richie te vergelijken met de prestaties van het bedrijf.


CEO

Richie Cunningham (53 yo)

1.1yrs

Tenure

US$1,819,383

Compensatie

Mr. Richard Anthony Cunningham, also known as Richie, is Chief Executive Officer and Director of Anebulo Pharmaceuticals, Inc. since October 2023. He served as Chief Executive Officer and Director at Tyme...


Leiderschapsteam

NaamPositieTenureCompensatieEigendom
Joseph Lawler
Founder & Chairman4.6yrsUS$83.11k46.27%
$ 17.5m
Richard Cunningham
CEO & Director1.1yrsUS$1.82mgeen gegevens
Daniel George
Principal Accounting Officer1.2yrsUS$194.25kgeen gegevens
Kenneth Cundy
Chief Scientific Officer2.5yrsUS$612.15k0%
$ 0

1.8yrs

Gemiddelde duur

53.5yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van ANEB wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 1.8 jaar), wat duidt op een nieuw team.


Bestuursleden

NaamPositieTenureCompensatieEigendom
Joseph Lawler
Founder & Chairman4.6yrsUS$83.11k46.27%
$ 17.5m
Richard Cunningham
CEO & Director1.1yrsUS$1.82mgeen gegevens
Bimal Shah
Independent Director1.1yrsUS$124.53k0%
$ 0
Kenneth Lin
Lead Independent Director3.8yrsUS$68.24k0%
$ 0
Areta Kupchyk
Independent Director3.6yrsUS$76.87k0%
$ 0
Jason Aryeh
Independent Director3.7yrsUS$83.24k0%
$ 0
Nathaniel Calloway
Independent Director2.1yrsUS$67.26k0%
$ 0
Aron English
Independent Director4.4yrsUS$66.87k17.95%
$ 6.8m
Andrew Monte
Member of Scientific Advisory Board3.8yrsgeen gegevensgeen gegevens
Arjun Chanmugam
Member of Scientific Advisory Board3.8yrsgeen gegevensgeen gegevens

3.7yrs

Gemiddelde duur

52yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van ANEB wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.7 jaar).